HOME >> BIOLOGY >> NEWS
Infant rats eagerly accept high concentrations of alcohol upon first exposure

  • Early exposure to alcohol is believed to enhance the risk of alcohol use and/or abuse later in life.
  • Research shows that infant rats are eager to accept high concentrations of alcohol upon first exposure.
  • This contrasts sharply with the standard rejection of alcohol by adult rats upon first exposure.
  • This finding may have implications for human infants.

Early exposure to alcohol is believed to enhance the risk of alcohol use and/or abuse later in life. A study in the August issue of Alcoholism: Clinical & Experimental Research examines the acceptance of alcohol by infant rats, finding that they are eager to ingest large amounts of highly concentrated alcohol during a short time period, resulting in extremely high concentrations of alcohol in the blood.

"There are numerous avenues for very early alcohol exposure, some depending upon culture," said Norman E. Spear, Distinguished Professor of psychology at Binghamton University and the study's corresponding author. "One way is through the milk of a breastfeeding mother who has consumed alcohol; this is likely since more than half of the pediatricians in the country tell their patients that breastfeeding may be facilitated by consuming alcohol beforehand. It is also common in some parts of Latin America, for example, to place a cotton ball soaked with alcohol on the stomach of a fussy infant, which brings relief in the presence of alcohol's odor, perhaps making it more attractive, and also results in some alcohol intake through inhalation or the skin. Alcohol is also given medicinally to infants in some cultures, placed in the fussy infant's bottle. In addition, exposure to alcohol's odor is likely when parents drink; it is known that this makes alcohol's odor more or less attractive to these children, depending on the circumstances of the drinking. The danger in all of this is that exposure to alcohol early in life may increase its attractiveness and l
'"/>


15-Aug-2004


Page: 1 2 3

Related biology news :

1. Infants sighs may reset breathing regulation mechanism as well as help lungs develop
2. Infants more vulnerable to serious brain injury from falling than previously thought
3. Researchers find a genetic connection in Sudden Infant Death Syndrome (SIDS)
4. Vanderbilt Medical Students Study Effects Of Vibration On Infant Health
5. New Insight Into Genetic Cause Of Infant Mortality
6. Molecular Basis Of Leading Genetic Cause Of Infant Death Discovered
7. 40% Of Developing World Infants Stunted
8. Researchers Unable To Document Existence Of Transient HIV Infection In Infants
9. Effects Of Age Of Introduction Of Complementary Foods On Iron Status OfBreast-Fed Infants In Honduras
10. Inhibitor Shows Potential To Protect Infant Brain
11. Hormone Activators Stimulate Skin Growth In Fetal Rats Suggesting Possible Skin Treatment For Premature Infants

Post Your Comments:
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... Drug Administration (CFDA) has approved the Company,s application to ... clear cell carcinoma (OCCC) patients for its proprietary drug ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... Washington, USA (PRWEB) March 29, 2015 ... and the United States and plenary talks by four ... SPIE Optics + Optoelectronics next month in ... technical presentations in 17 conferences alongside a two-day exhibition. ... and photonics , the event will run 13-16 April ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: